Osteosarcoma is a rare malignancy that is still lethal to approximately one third of the affected patients. Perioperative and palliative chemotherapy remain the therapeutic backbone of localized and advanced osteosarcoma, respectively. Novel targeted therapeutics for the treatment of osteosarcoma are urgently needed. Here, we will use a proteomic approach that is based on the biotinylation of bloodstream-accessible proteins to characterize the blood-tissue interface in primary tumors, as well as metastatic and pre-metastatic organs in the context of osteosarcoma. The results of this study will serve as a basis for the development of future antibody-based therapeutics for the treatment of osteosarcoma.

Here you can find further information.